Navigation Links
Greenphire CEO Sam Whitaker speaks on Sunshine Act and Clinical Trial Payments
Date:12/4/2012

KING OF PRUSSIA, Pa., Dec. 4, 2012 /PRNewswire-iReach/ -- Greenphire CEO Sam Whitaker spoke at the Sunshine Act and Aggregate Spend Bootcamp on the implications of the Physician Sunshine Act for the management of clinical trial payments and on advances in technology which streamlines financial reporting required to comply with the Act. 

The discussion focused on how pharmaceutical, biotech, and medical device companies can use technology to gather and report on required data on clinical trial payments, which present a particular tracking challenge because each clinical trial may involve a complex series of payments made to multiple physician investigators across multiple clinical sites.  To further complicate matters, payments may be made directly or by third parties like Contract Research Organizations (CROs).  Sam's discussion also focused on best practices in preparing for the Act and on the ancillary benefits to sponsor organizations of implementing data aggregation technologies across clinical trials, which include increased automation, tracking, and accountability, and reduced costs and risk.

The presentation took place on Tuesday, December 4, 2012 in Philadelphia, PA.  The Sunshine and Aggregate Spend Bootcamp is an intensive, hands-on seminar intended to prepare pharmaceutical and medical device companies for the requirements of complying with aggregate spend reporting under the Physician Sunshine Act.

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Autism Speaks announces the release of new genetic data for researchers
2. Autism Speaks and SAGE® Labs develop rat models for translational autism research
3. Autism Speaks awards nearly $2.9 million to fund autism research
4. Autism Speaks awards $1.1 million to fund high priority studies
5. Plant DNA speaks English, identifies new species
6. Sunshine, biofuel and the tides, oh my!
7. TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
8. Clinical hypnosis can reduce hot flashes after menopause, Baylor study shows
9. BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
10. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
11. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: